Regeneron Pharma stock: BARDA extends Inmazeb supply deal

Regeneron Pharma stock was quoted at EUR 733.05 by Lang & Schwarz at 5:05:26 p.m. Berlin time on October 29, 2026. That was 1.47 percent below the EUR 743.95 quote recorded at 12:46 p.m. in the earlier October 29 coverage, a move that independently qualifies this second main-value report.

The underlying company news dates to October 26. In its Regeneron release, the biotechnology company said it had extended its agreement with the Biomedical Advanced Research and Development Authority, or BARDA, to provide additional Inmazeb supply for U.S. Ebola preparedness.

Longer supply visibility

The agreement expands a procurement arrangement that began in 2020. Regeneron expects to deliver additional doses to the U.S. government through 2031 and receive approximately USD 270 million. Inmazeb is a three-antibody cocktail approved by the U.S. Food and Drug Administration for infection caused by Orthoebolavirus zairense in adults and pediatric patients, including neonates born to infected mothers.

The company said Inmazeb reduced mortality by approximately 55 percent compared with an active control treatment in patients with low viral load. That clinical figure relates to the treatment evidence and should not be read as a forecast for the contract's financial contribution.

Separate research program

The same announcement distinguishes the procurement agreement from a development program. Regeneron is adding investigational maftivimab, the most potent virus-neutralizing component of Inmazeb, to the PARTNERS trial as a potential treatment for Bundibugyo virus disease in an outbreak in the Democratic Republic of the Congo. The company cites positive laboratory and non-human-primate findings, while clinical effectiveness against that virus remains to be established.

Investor context

For investors, the contract provides a longer-dated government supply commitment, while the maftivimab program remains a research and clinical-development opportunity rather than an approved indication. Regeneron Pharmaceuticals, Inc. is listed on Nasdaq under ticker REGN and operates in healthcare biotechnology.

For broader market context, see the S&P 500 market overview. Investors can also follow the real-time quote of Regeneron Pharmaceuticals stock.

More news and analyses on Regeneron Pharmaceuticals stock.